Inspired by a convo w/ @IanRountree:
Hard to compete in some areas of bio w/ funds like Flagship or Atlas bc once something's working in the lab, their reach in tech transfer offices is so strong that they'll scoop it up. Feels like there's a corollary in OSS and Series A funds
-
-
+1 I wasn't referring to that as their moat, just a feature
-
unrelated, but a fascinating exercise is to map out how much of Kendall square is owned by either third rock, or groups that give third rock first right of refusal.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.